Dual GLP-1/GLP-2 receptor agonist peptide with biased signaling and prolonged pharmacokinetics
A first-in-class 33-amino-acid acylated peptide dual agonist of the glucagon-like peptide 1 and glucagon-like peptide 2 receptors developed by Zealand Pharma for the treatment of obesity and obesity-associated low-grade inflammation, distinguished from conventional incretin-class therapeutics by the addition of GLP-2-receptor-mediated intestinal barrier repair and anti-inflammatory activity to GLP-1-receptor-mediated anorectic and glucometabolic effects.
Abstract
Dapiglutide (ZP 7570; CAS 2296814-85-0; molecular formula C192H302N46O57; molecular weight 4166.79 g/mol) is a synthetic 33-amino-acid peptide dual agonist of the human glucagon-like peptide 1 receptor (GLP-1R) and glucagon-like peptide 2 receptor (GLP-2R) bearing a C18 fatty acid acyl modification that extends plasma half-life to approximately 123 to 129 hours and permits once-weekly subcutaneous administration [1, 2]. Developed by Zealand Pharma A/S (Copenhagen, Denmark) as a potential first-in-class agent for obesity and its inflammatory comorbidities, dapiglutide was designed to exploit the complementary pharmacology of the two incretin receptors: GLP-1R activation suppresses appetite, delays gastric emptying, and improves glucose homeostasis through cyclic adenosine monophosphate (cAMP)-dependent signaling in pancreatic beta cells, hypothalamic appetite circuits, and vagal afferents; GLP-2R activation promotes intestinal epithelial proliferation, enhances paracellular tight junction integrity, and suppresses mucosal inflammation through cAMP-dependent signaling in enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons [3, 4]. At the molecular level, dapiglutide exhibits biased agonism at the GLP-1R, displaying full agonist activity for cAMP formation while producing significantly blunted beta-arrestin recruitment, a signaling profile associated with reduced receptor desensitization and sustained intracellular cAMP production for up to 12 hours in vitro [5]. The compound entered clinical development in 2020 with a Phase 1 single-ascending-dose and multiple-ascending-dose trial in healthy volunteers demonstrating dose-proportional pharmacokinetics, a favorable safety profile dominated by mild gastrointestinal adverse events, and dose-dependent body weight reductions of up to 4.3 percent from baseline after four weeks of once-weekly dosing [1, 2]. A subsequent 13-week Phase 1b multiple-ascending-dose extension in 54 participants with overweight or obesity (BMI 27 to 40 kg/m2) reported placebo-adjusted body weight reductions of up to 8.3 percent, with no severe treatment-emergent adverse events [6]. The preclinical pharmacology of dapiglutide includes demonstration of intestinal barrier repair in murine short bowel syndrome models, where the compound promoted claudin-7 expression, tightened the paracellular leak pathway, improved oral glucose tolerance, reduced intestinal transit time, increased villus height and intestinal length, and reduced stool water losses [10, 11]. Zealand Pharma paused the dapiglutide program in 2025, citing portfolio prioritization in an increasingly competitive metabolic disease landscape, though the Phase 1b 28-week data were subsequently reported as positive [7, 12]. The compound is not approved in any jurisdiction. It is available from select research chemical suppliers for investigational use only.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.